MAGCELL® MICROCIRC Leads to Volume Reduction in Benign Prostate Hyperplasia (BPH)

Therapeutic Use of Pulsed Electromagnetic Field Therapy Reduces Prostate Volume and Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia. Andrology. 2020 Feb 23. doi: 10.1111/andr.12775. [Epub ahead of print] PubMed PMID: 32090492. Tenuta M, Tarsitano MG, Mazzotta P, Lucchini L, Sesti F, Fattorini G, Pozza C, Olivieri V, Naro F, Gianfrilli D, Lenzi A, Isidori AM, Pofi R.

Read on Press Release Point 20th March 2020

The treatment (2 x 5 min. daily) resulted in a significant volume reduction of the prostate after only 28 days of therapy (V1) compared to the start of treatment (V0).

That the therapy effect is sustainable is shown by the fact that even after 4 months (V2) there was a significantly reduced prostate volume compared to the start of treatment (V0).

The survey on quality of life (IPSS questionnaire: urination/quality of life) also showed significantly better results at both points in time (V1 and V2) than V0.

Overall, there was a rapid improvement in symptoms without changes in gonadal hormones or sexual function, with high compliance and without side effects.

MAGCELL® MICROCIRC leads to volume reduction in benign prostate hyperplasia (BPH) in a relatively short time

Best results were achieved in moderate to severe symptoms (LUTS) and patients without metabolic syndrome (MetS). 


  • Electrode-free electrotherapy for therapists and patients
  • Pulsating electromagnetic fields (PEMF)
  • Field strength more than 1000 gauss
  • Effective treatment concept due to repeatable short-treatment periods
  • Through-textile treatment (even through shoes)

PRICE: £485.00 including vat and delivery in the UK and Ireland.  

Please email for an order form which includes contraindications.

Read the diary of a gentleman using the Magcell Microcirc for BPH

Read about the success of Magcell Vetri in the canine model for BPH in The Prostate- Effect of pulsed electromagnetic field therapy on prostate volume and vascularity in the treatment of benign prostatic hyperplasia: A pilot study in a canine model